SPOTLIGHT: Repligen touts positive data

Repligen announced positive results from a Phase II clinical trial to evaluate the use of RG1068, synthetic human secretin, as an agent to improve the assessment of pancreatic duct structures by magnetic resonance imaging. The study showed an improvement in sensitivity of detection of structural abnormalities of the pancreatic duct of approximately 20 percent with no loss in specificity, consistent with prior data and expectations. Release